Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference20 articles.
1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med.,2010
2. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings;Lens;Recent Pat Anticancer Drug Discov.,2008
3. Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma;Margolin;Commun Oncol.,2008
4. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications;Di Giacomo;Semin Oncol.,2010
Cited by 388 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors;Cancers;2024-01-05
2. Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist;Current Dermatology Reports;2023-11-30
3. Single and combination immunotherapy with chemotherapy and the risk of AKI in patients with solid cancer;Clinical and Experimental Nephrology;2023-11-23
4. Immune Checkpoint Inhibition;Side Effects of Cancer Therapy;2023-10-31
5. Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways;Medical Oncology;2023-10-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3